Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + raltitrexed
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Gefitinib + raltitrexed is a combination of two small molecule anticancer drugs used in clinical research for the treatment of advanced or refractory colorectal cancer. Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways involved in tumor cell proliferation and survival. Raltitrexed is a thymidylate synthase inhibitor and folic acid antagonist that disrupts DNA synthesis by inhibiting the production of thymidine triphosphate. The combination has been studied as second-line chemotherapy for patients with colorectal cancer who have progressed after first-line therapy. Clinical trials indicate the regimen is generally well tolerated but does not significantly improve progression-free survival compared to raltitrexed alone[3][4].
- Brand names
- IressaTomudex
- Other names
- gefitinib + raltitrexed combination
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TS (Thymidylate synthase)
Beyond the preview
Go deeper on gefitinib + raltitrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + raltitrexed.